2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
5
Phase 3
3
Phase 1/2
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Myeloid
2
Other hematologic neoplasm
1
Conditions
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Hematologic Neoplasms
1
Interventions
Cisplatin
726
Carboplatin
609
Paclitaxel
579
Cyclophosphamide
516
Radiotherapy
511
Docetaxel
477
Fluorouracil
454
Gemcitabine
438
Doxorubicin
383
Capecitabine
362
Dexamethasone
328
Oxaliplatin
289
pembrolizumab
283
Leucovorin
283
Bevacizumab
275
Etoposide
272
Vincristine
270
Rituximab
246
Prednisone
223
Pemetrexed
217
Cytarabine
205
Drug Therapy
194
Trastuzumab
176
Irinotecan
174
Methotrexate
171
Lenalidomide
137
Nivolumab
136
Filgrastim
135
Epirubicin
129
Tamoxifen
128
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
fedratinib
×
Clear all
NCT03952039
2025-08-28
FREEDOM2
Celgene
Phase 3
Completed
202 enrolled
23 charts
NCT01437787
2025-03-05
JAKARTA
Bristol-Myers Squibb
Phase 3
Completed
289 enrolled
1 FDA
NCT03755518
2024-12-12
FREEDOM
Celgene
Phase 3
Terminated
38 enrolled
23 charts